摘要:
The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.
摘要:
Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.
摘要:
Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.
摘要:
A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are independently hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, R.sup.7 R.sup.8 N-- (wherein R.sup.7 and R.sup.8 are independently hydrogen or C.sub.1-3 alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or --O(CH.sub.2).sub.l OR.sup.19 (wherein R.sup.19 is hydrogen or C.sub.1-3 alkyl, and l is 1,2 or 3); or when located at the ortho position to each other, R.sup.1 and R.sup.2, or R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH--; or when located at the ortho position to each other, R.sup.1 and R.sup.2 together form --OC(R.sup.15 l) (R.sup.16)O-- (wherein R.sup.15 and R.sup.16 are independently hydrogen or C.sub.1-3 alkyl); Y is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --CH.dbd.CH-- or -- CH.dbd.CH--CH.sub.2 --; and Z is --Q--CH.sub.2 WCH.sub.2 --CO.sub.2 R.sup.12, ##STR2## (wherein Q is --C(O)--, --C(OR.sup.13).sub.2 -- or --CH(OH)--; W is --C(O)--, --C(OR.sup.13).sub.2 -- or --C(R.sup.11) (OH)--; R.sup.11 is hydrogen atom or C.sub.1-3 alkyl; R.sup.12 is hydrogen or R.sup.14 (wherein R.sup.14 is physiologically hydrolyzable alkyl or M (wherein M is NH.sub.4, sodium, potassium, 1/2 calcium or a hydrate of lower alkyl amine, di-lower alkyl amine or tri-lower alkyl amine)); two R.sup.13 are independently primary or secondary C.sub.1-6 alkyl; or two R.sup.13 together form --(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.3 ; R.sup.17 and R.sup.18 are independently hydrogen or C.sub.1-3 alkyl; and R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.2-3 alkenyl, C.sub.3-6 cycloalkyl, ##STR3## wherein R.sup.9 is a hydrogen atom, C.sub.1-4 alkyl, C.sub.1-3 alkoxy, fluoro, chloro, bromo or trifluoromethyl), phenyl--(CH.sub.2).sub.m -- (wherein m is 1,2 or 3), --(CH.sub.2).sub.n CH(CH.sub.3)--phenyl or phenyl--(CH.sub.2).sub.n CH(CH.sub.3)-- (wherein n is 0,1 or 2).
摘要:
The present invention provides a compound of the formula: ##STR1## process for their production, pharmaceutical compositions containing them and their pharmaceutical uses, and intermediates useful for their production and processes for the production of such intermediates.
摘要:
A method for producing a sintered ferrite magnet having an M-type ferrite structure and represented by: Ca1−x−yRxBayFe2n-zCoz, (by atomic ratio), where 0.3≦1−x−y≦0.65, 0.2≦x≦0.65, 0.001≦y≦0.2, 0.03≦z≦0.65, 4≦n≦7, and 1−x−y>y. The method includes mixing a Ca compound, an R element compound, a Ba compound, an iron compound and a Co compound as starting materials; calcining the starting materials to obtain calcined bodies; pulverizing the calcined bodies to obtain a calcined powder; providing recycled materials having an M-type ferrite structure and being represented by the above formula; pulverizing the recycled materials to obtain a recycled material powder; mixing the recycled material powder with the calcined powder to form a moldable material; molding the moldable material to obtain green bodies; and sintering the green bodies to obtain the sintered ferrite magnet.
摘要翻译:一种具有M型铁氧体结构的烧结铁氧体磁体的制造方法,其特征在于,以Ca1-x-yRxBayFe2n-zCoz(原子比)表示,其中0.3≤1-xy≤0.65,0.2≤x≤0.65,0.001 @ y@0.2,0.03 @ z @ 0.65,4 @ n @ 7和1-xy> y。 该方法包括混合Ca化合物,R元素化合物,Ba化合物,铁化合物和Co化合物作为起始材料; 煅烧原料以获得煅烧体; 粉碎煅烧体以获得煅烧粉末; 提供具有M型铁氧体结构并由上式表示的再循环材料; 粉碎回收材料以获得再生材料粉末; 将再生材料粉末与煅烧粉末混合以形成可模制材料; 模制可模制材料以获得生坯体; 并烧结生坯以获得烧结的铁氧体磁体。
摘要:
The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
摘要:
A sintered ferrite magnet having an M-type ferrite structure and comprising Ca, an R element which is at least one rare earth element indispensably including La, Ba, Fe and Co as indispensable elements, which is represented by Ca1-x-yRxBayFe2n-zCoz, wherein (1−x−y), x, y, z and n are numbers representing the amounts of Ca, the R element, Ba and Co and a molar ratio, meeting 0.2≦x≦0.65, 0.001≦y≦0.2, 0.03≦z≦0.65, and 4≦n≦7.
摘要:
The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.
摘要:
An audio speaker bracket for use in passenger vehicles and a method for installing the speaker to a mounting panel using at feast one suspension member. The method permits the speaker to be temporarily supported by a mounting panel while secure attachment of the bracket to the mounting panel is completed.